Severe combined immunodeficient (SCID) mice were found to be highly susceptible to murine cytomegalovirus (MCMV) infection. Treatment of infected mice with ganciclovir (12.5, 25, and 50 mg/kg of body weight for 10 days) starting 24 h after virus challenge resulted in delays in death by 2 to 8 days, and no animals survived the infection. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) was much more potent, with doses of 1, 3.2, and 10 mg/kg/day (for 10 days) increasing the mean survival time by 15 to 30 days. Twenty-day treatments with HPMPC starting 5 days after virus inoculation increased the mean survival time by 24 to 32 days, with once-weekly (50-mg/kg) treatments being equivalent to daily (10-mg/kg) treatments.
Human cytomegalovirus (HCMV) causes generally benign disease in normal adult individuals with competent immune systems, but it causes serious infections in newborns (32) and immunosuppressed adults (17, 19) . The two U.S. Food and Drug Administration-approved drugs for the treatment of HCMV infections (ganciclovir [GCV] and foscarnet) have toxic side effects (11, 29) , and the emergence of drugresistant viruses (6) occurs during treatment. Thus, the search for new therapies of HCMV disease is warranted. The nucleotide analog (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) is a promising new agent with potent anti-HCMV (27) and anti-murine cytomegalovirus (MCMV [10] ) activities. Other types of substances which have been investigated for their efficacies against CMV infections include interferon (4, 8) and the interferoninducing biological response modifier 2-amino-5-bromo-6phenyl-4(3H)-pyrimidinone (bropirimine [1, 2] ). Interferon and bropirimine are immunomodulatory substances.
In the study described here, we investigated the antiviral activities of GCV, HPMPC, recombinant alpha interferon A/D (rIFN-a A/D), and bropirimine against MCMV infections in genetically immunosuppressed mice. Since HCMV does not infect rodents, the related MCMV (9, 10) was used to evaluate these antiviral agents. Recent National Institutes of Health recommendations (12) indicate the need to evaluate treatments in immunosuppressed animals in order to correlate the results to appropriate treatments in humans with the disease. We recently developed two MCMV infection models in mice immunosuppressed by cyclophosphamide treat-* Corresponding author. ment (24) or as a result of Friend leukemia virus infection (26) . In this study, we investigated MCMV infection in severe combined immunodeficient (SCID) mice as a new model for studying the treatment of such infections. SCID mice, or C.B-17 scid/scid mice, are a congenic partner strain of BALB/cAnIcr, which lacks functional T or B cells (22) . Consequently, these mice are hypogammaglobulinemic and poor mitogenic responders, and they fail to reject allogenic skin grafts. Other hematopoietic cell types (monocytes, granulocytes, and natural killer cells), however, are present and function normally (22) . Our results indicate that treatment with HPMPC is highly effective in delaying the time to death, that GCV is less effective, and that rIFN-a A/D and bropirimine are inactive in this model.
MATERUILS AND METHODS
Compounds. The GCV used in this study was purchased from a local hospital pharmacy. HPMPC was synthesized at the Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague. Each compound was dissolved in sterile physiological saline solution and then filter sterilized for injection into animals. Sterile saline served as a placebo control. The human rIFN-a A4al/ot2 which has been shown by other investigators (7) to be active against herpesvirus infections in mice, was kindly provided by Jerome Schwartz, Schering Corporation, Bloomfield, N.J. It was solubilized in phosphate-buffered saline (pH 7.5). Bropirimine, a poorly soluble material, was suspended in a saline solution containing 0.4% high-viscosity carboxymethyl cellulose. Doses of GCV, HPMPC, and bropirimine were selected on the basis of our experience and that of others for the treatment of MCMV infections (1, 10, 24) . Doses of rIFN-ot were chosen on the basis of the antiviral activity of interferon against an unrelated virus (23) and for cost considerations. Oxytetracycline, which was obtained from a local farm supply store, was dissolved in the animals' drinking water (filter sterilized) at a final concentration of 60 ,ug/ml, to inhibit secondary bacterial infections. As a prophylaxis against Pneumocystis caninii pneumonia, which is known to occur in SCID mice (13) , the animals were also fed wafers containing trimethoprim and sulfamethoxazole (40 and 200 mg, respectively; BioServ, Frenchtown, N.J.) on a weekly basis.
Virus titrations. The Smith strain of MCMV was obtained from the American Type Culture Collection, Rockville, Md. The virus was prepared for animal studies by passage in 3-week-old specific-pathogen-free Swiss Webster mice, which were killed 12 days after intraperitoneal (i.p.) injection of a sublethal dose. Ten percent homogenates of salivary glands containing the virus were prepared in cell culture medium. The homogenates were clarified by centrifugation at 600 x g for 10 min at 4°C, and aliquots were stored at -80°C in cryotubes. During antiviral studies, the virus titers in tissues were determined by using mouse embryo fibroblast cells (25) in 96-well plates. On the indicated days after virus challenge, five mice in each group were killed and dissected; each tissue sample was homogenized and titrated separately. Wells that were positive for virus after 7 days were used in determining 50% end points, which were calculated by the method of Reed and Muench (15) . Mean virus titers were expressed as log10 50% cell culture infectious doses per gram of tissue.
Animal infection. SCID mice breeding pairs were originally obtained from Norman Klinman, Scripps Institute, La Jolla, Calif. The progeny mice used in the experiments described here were housed in microisolator cages (Lab Products, Maywood, N.J.) containing sterilized bedding, food, and water. The cages were maintained in HEPAfiltered horizontal laminar flow hoods (Lab Products). Ten mice were in each MCMV-infected group, and five uninfected animals per group served as toxicity controls. Animals (4 to 6 weeks old) were infected i.p. with 103 PFU of virus per mouse for all studies except those for which the results are given in Fig. 3 (104-5 PFU per mouse). Treatments started either 24 h (most studies) or 5 days (see Fig. 3 ) after virus inoculation and were given i.p., as follows: GCV, twice daily for 10 days; HPMPC, once daily for 10 days or once weekly (50 mg/kg of body weight) for 4 weeks; rIFN-ot, once daily for 10 days; and bropirimine, once every 3 days through day 18. The evaluation of a once-weekly treatment regimen with HPMPC was based on a report indicating the prolonged effects of the nucleotide against herpes simplex virus in mice (31) . Bropirimine was administered infrequently to avoid the hyporesponsive phenomenon that occurs with interferon inducers (28) . The parameters used to assess antiviral activity included increased numbers of survivors and mean survival time and decreased tissue virus titers. Drug-induced toxicities were assessed in uninfected SCID mice treated in parallel with MCMV-infected animals and at higher doses in normal BALB/c mice (Simonsen Labs, Gilroy, Calif.). Death, weight loss, and failure to gain weight were determined, with weight determinations made before the first treatment and 24 h after the final treatment with each agent.
Statistical methods. The increased numbers of survivors were statistically assessed by the two-tailed Fisher exact test. Increases in the mean day to death and reductions in Toxic effects of compounds in mice. None of the compounds, at any of the doses evaluated in the antiviral studies (GCV, 12.5, 25, and 50 mg/kg; HPMPC, 1, 3.2, and 10 mg/kg; rIFN-a A/D, 1 X 104 and 5 x 104 U per mouse; bropirimine, 100 and 300 mg/kg), caused death or prevented mice from gaining weight relative to the effects of placebo controls in uninfected animals. In follow-up evaluations, the relative toxicities of GCV and HPMPC were determined by using doses higher than those used in the antiviral studies. In order to be more certain that the deaths were drug related, normal uninfected BALB/c mice instead of SCID mice were used for these determinations. The results showed that GCV and HPMPC had approximately equal toxicities (Table 1) , causing death in nearly all mice when they were used at doses of 150 and 300 mg/kg, but they showed no lethal effects at a dose of 75 mg/kg over a 10-day treatment regimen. Deaths caused by HPMPC treatments were delayed relative to those in the GCV-treated groups, suggesting a different mode of toxicity.
Antiviral activities of GCV and HPMPC. Treatments with GCV and HPMPC provided some benefit against MCMV infection in SCID mice (Fig. 1) . Daily GCV doses of 12.5, 25, and 50 mg/kg caused increases in mean survival times of 1.7 (P was not statistically significant), 4.8 (P < 0.001), and 8.4 (P < 0.001) days relative to those for the placebo controls. None of the GCV-treated animals survived the infection, however. Based on the results of previous work (10), we expected HPMPC to be much more potent than GCV for inhibiting MCMV in the animal model described here, so we treated the animals with fairly low doses. Indeed, dramatic increases in mean day to death were achieved by daily treatments of 1, 3.2, and 10 mg/kg, which caused increases in mean survival times (P < 0.001) of 15.2, 18.4, and 30.2 days relative to those of the placebo controls. The 1-mg/kg dose of HPMPC delayed death longer than the highest (50 mg/kg) dose of GCV did. At 90 days (the end of the experiment), two mice in the 10-mg/kg treatment group were alive and healthy (P was not statistically significant). In a subsequent experiment, virus titers in livers, lungs, k-8.0 Gland
CD0 W1 f spleens, and salivary glands were determined at several time points in mice treated with GCV (25 mg/kg), HPMPC (1 mg/kg), or placebo (Fig. 2) . Virus titers in the salivary glands of the placebo group were 104 log1o on day 8 of the infection (the earliest time point assayed), but virus was not detected in the livers, lungs, or spleens until day 11. Virus was not detected in the salivary glands of GCV-treated mice on day 8, and the rises in virus titer in salivary glands lagged behind those in the virus titers in the salivary glands of mice in the placebo group. Virus titers in the livers, lungs, and spleens became detectable by day 23 in GCV-treated mice and then increased rapidly after that. In contrast to the effect of GCV, HPMPC did not suppress virus titers in the salivary glands relative to those in the salivary glands of the placebo controls. However, virus titers in livers, lungs, and spleens were suppressed for a longer period of time by HPMPC than by GCV treatments. Delays in the development of virus titers in these tissues in the drug-treated groups correlated with extensions in the mean survival times relative to the mean survival times of mice in the placebo control group. Because two of the HPMPC-treated mice survived the infection for 90 days by a 10-day treatment regimen, it was thought that a longer course of therapy might give even more dramatic results. To test this hypothesis in a well-established MCMV infection, mice were treated with HPMPC for 20 days starting 5 days after virus challenge (Fig. 3) . The infecting dose of virus was also increased to 104 5 PFU per mouse to develop a more rapid infection. The results did not confirm the hypothesis, however, since none of the animals survived past 60 days. Doses of 2.5, 5, and 10 mg/kg given for 20 days extended the survival times by 24.6, 27.2, and 32.2 days, respectively, which was not appreciably longer than those obtained by the 10-day regimen. Apparently, a delay in the time of HPMPC treatment relative to the time of virus inoculation coupled with an increased viral challenge ILpiee Treatments started 5 days after virus inoculation. Symbols: for once-daily treatments, 0, placebo; 0, HPMPC at 2.5 mg/kg/day; *, HPMPC at S mg/kg/day; A, HPMPC at 10 mg/kg/day. For once-weekly treatment, El, HPMPC at 50 mg/kg/week. dose may have contributed to these less than dramatic results. As part of the experiment described above, a higher (50 mg/kg) dose of HPMPC was evaluated in parallel by using a once-weekly treatment regimen. The 50-mg/kg dose administered once a week over a 22-day period proved to be nearly as effective at increasing the mean survival time (by 31.3 days) as the 10-mg/kg daily dose given for 20 days (mean survival time increase, 32.2 days). There was no statistically significant difference between the mean survival times in the two treatment groups. Antiviral activities of rIFN-a and bropirimine. Treatments with rIFN-oa (1 x 104 or 5 x 104 U/day) and bropirimine (100 or 300 mg/kg given every 3 days) provided no protection from MCMV infection in SCID mice. All deaths in the placebo and drug-treated groups occurred between 17 and 23 days, and none of the mice survived the infection. Virus titers in tissues were not assessed as part of these experiments, since no increases in mean survival time were observed, suggesting that virus replication was similar in placebo-treated and immunomodulator-treated groups.
DISCUSSION
The finding that short-term GCV treatments are not sufficient for protecting mice from progressive lethal MCMV disease in the SCID mouse model is similar to results we recently reported for BALB/c mice immunosuppressed with cyclophosphamide (24) . Likewise, in humans infected with HCMV, discontinuation of GCV therapy also leads to a relapse of the disease (12) . Even in normal mice, GCV is not able to suppress MCMV replication in tissues following discontinuation of therapy (10) . On the other hand, HPMPC has been shown to be much more effective in suppressing virus titers in tissues (10) , and this may account for the dramatic increases in the life spans of mice treated with this agent. Since a rebound of the disease occurred in mice treated with both compounds, the results indicate that animals with established MCMV infections must be treated continuously in order to be kept alive. Based on the results shown in Fig. 3 , the possibility exists that HPMPC could be used to treat humans on a once-weekly basis, whereas GCV must be given to humans intravenously on a daily basis (11) . This would make HPMPC administration more convenient, and the regimen would be considerably more cost-effective.
In toxicity evaluations, GCV and HPMPC were approximately equally toxic to uninfected BALB/c mice, with 50% lethal doses between 75 and 150 mg/kg for the 10-day treatment regimen. Since HPMPC at 1 mg/kg extended life in MCMV-infected animals longer than did GCV at 50 mg/kg, the relative potency and therapeutic index (antivirally active dose divided by the minimally toxic dose) of HPMPC is at least 50-fold greater than that of GCV. We did not determine the toxicities of GCV and HPMPC between the nontoxic (75 mg/kg) and overtly toxic (150 mg/kg) doses to calculate precise therapeutic indices. Arbitrarily, if the toxicities of GCV and HPMPC were each set at 100 mg/kg, and the antivirally active doses were established at 50 mg of GCV per kg or 1 mg of HPMPC per kg, then the in vivo therapeutic indices of GCV and HPMPC would be 2 and 100, respectively. In humans, the therapeutic index of GCV against HCMV disease is low, since the 5-mg/kg dose required to treat disease has toxic side effects (11) . The >50-fold in vivo potency difference between HPMPC and GCV correlates well with unpublished results we have obtained with the two compounds in plaque reduction assays (the 50% effective doses of HPMPC and GCV were 0.1 and 6 ,M, respectively, which is a 60-fold difference in potency).
Recently, Neyts et al. (14) published results of antiviral studies that they conducted using GCV and HPMPC to treat MCMV-infected SCID mice. They treated mice with the two compounds for 5 days starting 2 h after virus challenge and achieved extensions in mean survival times similar to those reported here. Their infecting virus challenge dose was higher than ours, since placebo-treated mice died within 10 days of infection. In a separate experiment, they also treated mice for 4 days with 50 mg of HPMPC per kg starting 4 days after virus inoculation, and the animals lived until about day 42. Those results and the results of daily tissue virus titers were similar to the results presented here, except for the effect of HPMPC on salivary gland virus titers. Using an HPMPC dose of 10 mg/kg, Neyts and colleagues (14) showed complete suppression of salivary gland virus titers for 6 days after the start of the rise in titers in the placebo control. In contrast, the 1-mg/kg dose of HPMPC we used did not inhibit salivary gland virus replication relative to that in placebo-treated mice. These data suggest that HPMPC (at the 1-mg/kg dose) circulates poorly into salivary gland tissue or is poorly metabolized to its active antiviral state compared with its circulation and metabolism in the liver, lung, and spleen. Our work differed from that of Neyts et al. (14) in that they did not define toxicities of GCV and HPMPC, did not conduct 10-to 20-day treatment regimens, and did not evaluate HPMPC on a once-weekly treatment schedule.
Reports of whether rIFN-a provides any true benefit against MCMV infections in other murine models have depended on the model system used (4, 8) , but in general, the effects have been minimal. The studies (4, 8) were conducted in immunocompetent mice in which cell-mediated and humoral factors were also able to help contain the virus. In the SCID mouse model, the virus ultimately replicates to high titers and kills the host, since important immune factors are absent. Bropirimine, besides being an IFN inducer, also activates B and T cells. The latter effect was implicated in the anti-MCMV activity of bropirimine in normal mice (2) . Since SCID mice lack functional B and T cells (22) , bropirimine would not be immunostimulatory by this mechanism. One immune function that can be stimulated in SCID mice is that of natural killer cells (22) . Natural killer cells are known to play a role in the host defense against MCMV (30) , and both IFN and bropirimine (via IFN induction) activate these 1840 SMEE ET AL, TREATMENT OF CMV IN SCID MICE 1841 cells (16) . Since rIFN-a and bropirimine both failed to delay death caused by MCMV in SCID mice relative to the time of death of the placebo controls, the involvement of natural killer cells in suppressing virus titers in tissues (and, thus a delay in the time to death) was minimal. Several immunosuppression models of MCMV infection have been used in the past to study antiviral agents. These include normal mice treated with cortisone and antilymphocyte serum (18) , cyclophosphamide-treated animals (24) , and animals infected with Friend leukemia (26) or LP-BM5 (5) retroviruses. Athymic nude mice are also highly susceptible to MCMV infection (20) , but to our knowledge, they have not been used in published chemotherapy experiments. In comparing the models described above and the SCID model, disease progression following the discontinuation of drug therapy occurs only in SCID and cyclophosphamide-treated mice. This makes these two models more analogous than the other models to HCMV disease in patients with AIDS (11) . Both of these models are similar in many respects. As indicated above, the mice become increasingly ill and die from MCMV disease after the termination of drug therapy. Virus titers in tissues increase daily as death approaches, and low infecting virus inocula eventually kill the animals. One difference between the models is that cyclophosphamide-treated infected mice develop significant pneumonitis (21) , whereas we observed only a mild pneumonitis in SCID mice when lung sections were examined histologically. Although cyclophosphamide treatment of normal mice may be a less expensive method than maintaining a SCID mouse colony, there is one serious drawback to the former model. Cyclophosphamide treatments lead to toxicity and death by about 40 days after the start of treatment with the agent (24) . Thus, many of the experiments described in this report could not have been successfully completed by using the cyclophosphamide model. The SCID mouse model is the only one available that allows the chemotherapy of MCMV infections to be studied for several months.
